Select committee: Health and Social Care Committee
Future cancer
Closed
Opened 21 Mar 2023
Closed 30 May 2024
Health and Social Care Committee Inquiry on parliament.uk ↗
Inquiry scope (the committee's words)
The Future Cancer inquiry will explore innovations in cancer diagnosis and treatment. It will look at the innovations with the greatest potential to transform cancer diagnosis and treatment for patients in the short, medium and long term, and it will examine how innovations in diagnosing and treating cancer can best be transitioned into frontline clinical settings. It will also explore international examples of best practice. Types of innovations that could be examined by the inquiry range from medicines and vaccines to artificial intelligence. This inquiry builds on the Committee's recent work on cancer services, including its report in April 2022, which was focused largely on current provision of cancer services and the impact of the covid-19 pandemic.
Where it stands
The inquiry is closed, opened 21 March 2023.
The committee has not published a report yet.
Evidence
- 6 oral evidence sessionsLatest 29 January 2024
- 87 written submissions
- 25 witnesses
Recent activity
- Chair to Secretary of State for Health and Social Care on Future Cancer 23.05.2428 May 2024, Correspondence
- Boehringer Ingelheim Ltd7 May 2024, Written evidence · FCR0088
- Dr Paul Mulholland, University College London7 February 2024, Written evidence · FCR0087
Oral evidence sessions
On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.
| Date | Session and witnesses | Source |
|---|---|---|
| 29 Jan 2024 |
Oral Evidence
Dame Cally Palmer · NHS England,
Professor Peter Johnson · NHS England,
Rt Hon Andrew Stephenson · Department of Health and Social Care
|
View ↗ |
| 9 Jan 2024 |
Oral evidence session
Dr Julie Gralow · American Society of Clinical Oncology,
Dr Paul Mullholland · University College London and University College London Hospitals,
Professor David Baldwin · School of Medicine (University of Nottingham),
Professor David Chang · University of Glasgow,
Professor Mark Lawler · Queen's Univeristy Belfast
|
View ↗ |
| 28 Nov 2023 |
Oral evidence session
James Hargrave · Keep Up With Cancer,
Julian Beach · Medicines and Healthcare products Regulatory Agency (MHRA),
Professor Paul Dalby · University College London,
Sarah Byron · National Institute for Health and Care Excellence (NICE),
Tony Hickson · Cancer Research Horizons and Cancer Research UK
|
View ↗ |
| 14 Sep 2023 |
Oral evidence session
Dr Robin Buckle · Medical Research Council,
Dr Susan Galbraith · AstraZeneca,
Professor Kevin Harrington · Institute of Cancer Research,
Professor Sir John Bell · Oxford University
|
View ↗ |
| 19 Jul 2023 |
Oral evidence session
Marcel Gehrung, PhD · Cyted,
Professor Matt Brown · Genomics England,
Professor Stephen Duffy · Wolfson Institute of Population Health (Queen Mary University of London),
Sara Hiom · GRAIL Europe
|
View ↗ |
| 21 Jun 2023 |
Oral evidence session
Anna Jewell · Less Survivable Cancers Taskforce,
Gemma Peters · Macmillan Cancer Support,
Jane Lyons · Cancer52,
Michelle Mitchell OBE · Cancer Research UK
|
View ↗ |
Written evidence
On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.
| Reference | Date | Submitter |
|---|---|---|
| FCR0088 | 7 May 2024 | Boehringer Ingelheim Ltd |
| FCR0087 | 7 Feb 2024 | Dr Paul Mulholland, University College London |
| FCR0086 | 16 Jan 2024 | Professor David Baldwin, Nottingham University Hospitals NHS Trust |
| FCR0085 | 16 Jan 2024 | Maggie's |
| FCR0084 | 19 Dec 2023 | Institute of Biomedical Science |
| FCR0082 | 29 Nov 2023 | Open Medical |
| FCR0081 | 29 Nov 2023 | Neil Daly, Skin Analytics |
| FCR0083 | 29 Nov 2023 | Endoscope-i |
| FCR0080 | 6 Sep 2023 | Cancer52 |
| FCR0079 | 6 Sep 2023 | Macmillan Cancer Support |
| FCR0015 | 28 Jun 2023 | Professor Miriam Dwek, University of Westminster |
| FCR0014 | 28 Jun 2023 | Brain Tumour Research |
| FCR0013 | 28 Jun 2023 | The Newcastle upon Tyne Hospitals NHS Foundation Trust |
| FCR0012 | 28 Jun 2023 | Boots UK |
| FCR0011 | 28 Jun 2023 | The University of Manchester |
| FCR0010 | 28 Jun 2023 | Dr Heather Williams, The Christie NHS Foundation Trust |
| FCR0009 | 28 Jun 2023 | Kidney Cancer UK |
| FCR0008 | 28 Jun 2023 | Breast Cancer Now |
| FCR0007 | 28 Jun 2023 | Alastair Travis, Silverbird Ltd |
| FCR0006 | 28 Jun 2023 | UK Focused Ultrasound Foundation |
| FCR0005 | 28 Jun 2023 | Action Against Heartburn |
| FCR0004 | 28 Jun 2023 | Yorkshire & Humber Academic Health Science Network |
| FCR0003 | 28 Jun 2023 | Anthony Nolan |
| FCR0002 | 28 Jun 2023 | Advanced Accelerator Applications, a Novartis company |
| FCR0001 | 28 Jun 2023 | Prof Wladyslaw Gedroyc, Imperial College Healthcare NHS Trust |
| FCR0030 | 28 Jun 2023 | MAP Patient Access |
| FCR0029 | 28 Jun 2023 | Imaging and Dosimetry for Molecular Radiotherapy Glenn Flux, Royal Marsden Hospital |
| FCR0028 | 28 Jun 2023 | Professor Stephen W. Duffy, Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London |
| FCR0027 | 28 Jun 2023 | Leeds University Medical School |
| FCR0026 | 28 Jun 2023 | Cyted |
| FCR0025 | 28 Jun 2023 | Cancer Research UK Cambridge Centre |
| FCR0024 | 28 Jun 2023 | GRAIL |
| FCR0023 | 28 Jun 2023 | Dr Laura Wareing, Lancaster University |
| FCR0022 | 28 Jun 2023 | NICE (National Institute for Health and Care Excellence) |
| FCR0021 | 28 Jun 2023 | Young Lives vs Cancer |
| FCR0020 | 28 Jun 2023 | School of Health Sciences, University of Surrey |
| FCR0019 | 28 Jun 2023 | Mrs Claire Bode, Worcestershire Acute Hospitals NHS Trust |
| FCR0018 | 28 Jun 2023 | Macmillan Cancer Support |
| FCR0017 | 28 Jun 2023 | Society of Clinical Injury Lawyers |
| FCR0016 | 28 Jun 2023 | British In Vitro Diagnostics Association (BIVDA) |
| FCR0045 | 28 Jun 2023 | Blood Cancer UK |
| FCR0044 | 28 Jun 2023 | The Royal College of Surgeons of Edinburgh |
| FCR0043 | 28 Jun 2023 | 18 Week Support |
| FCR0042 | 28 Jun 2023 | AstraZeneca UK |
| FCR0041 | 28 Jun 2023 | Society and College of Radiographers |
| FCR0040 | 28 Jun 2023 | The Royal College of Radiologists (RCR) |
| FCR0039 | 28 Jun 2023 | Mr Stephen West, UHCW, Walsgrave Hospital, Clifford Bridge Road, Coventry, CV2 2DX |
| FCR0038 | 28 Jun 2023 | Cancer52 |
| FCR0037 | 28 Jun 2023 | Astellas Pharma Ltd. |
| FCR0036 | 28 Jun 2023 | Future Targeted Healthcare Manufacturing Hub |
Who gave evidence
On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.
| Witness | Organisation | Sessions |
|---|---|---|
| Anna Jewell · Chair | Less Survivable Cancers Taskforce | 1 |
| Dame Cally Palmer · National Cancer Director | NHS England | 1 |
| Dr Julie Gralow · Executive Vice President and Chief Medical Officer | American Society of Clinical Oncology | 1 |
| Dr Paul Mullholland · Honorary Associate Professor and Consultant in medical oncology | University College London and University College London Hospitals | 1 |
| Dr Robin Buckle · Chief Science Officer | Medical Research Council | 1 |
| Dr Susan Galbraith · Executive Vice President of Oncology Research & Development | AstraZeneca | 1 |
| Gemma Peters · Chief Executive Officer | Macmillan Cancer Support | 1 |
| James Hargrave · Vice-Chair | Keep Up With Cancer | 1 |
| Jane Lyons · Chief Executive Officer | Cancer52 | 1 |
| Julian Beach · Interim Executive Director, Healthcare Quality and Access | Medicines and Healthcare products Regulatory Agency (MHRA) | 1 |
| Marcel Gehrung, PhD · Co-founder and Chief Executive Officer | Cyted | 1 |
| Michelle Mitchell OBE · Chief Executive Officer | Cancer Research UK | 1 |
| Professor David Baldwin · Consultant Respiratory Physician and Honorary Professor of Medicine | School of Medicine (University of Nottingham) | 1 |
| Professor David Chang · Co-Lead of Precision-Panc, and Chair of Surgical Oncology | University of Glasgow | 1 |
| Professor Kevin Harrington · Head of the Division of Radiotherapy and Imaging | Institute of Cancer Research | 1 |
| Professor Mark Lawler · Board Member (European Cancer Organisation), and Associate Pro-Vice-Chancellor and Professor of Digital Health | Queen's Univeristy Belfast | 1 |
| Professor Matt Brown · Chief Scientific Officer | Genomics England | 1 |
| Professor Paul Dalby · Co-Director of the Future Targeted Healthcare Manufacturing Hub; Deputy Head of the Department of Biochemical Engineering | University College London | 1 |
| Professor Peter Johnson · National Clinical Director for Cancer | NHS England | 1 |
| Professor Sir John Bell · Regius Professor of Medicine | Oxford University | 1 |
| Professor Stephen Duffy · Professor of Cancer Screening | Wolfson Institute of Population Health (Queen Mary University of London) | 1 |
| Rt Hon Andrew Stephenson · Minister of State (Minister for Health and Secondary Care) | Department of Health and Social Care | 1 |
| Sara Hiom · Vice President, NHS Implementation & External Affairs | GRAIL Europe | 1 |
| Sarah Byron · Programme Director of Devices, Diagnostics and Digital | National Institute for Health and Care Excellence (NICE) | 1 |
| Tony Hickson · Chief Business Officer | Cancer Research Horizons and Cancer Research UK | 1 |
Correspondence
On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.
| Published | Direction | Letter |
|---|---|---|
| 28 May 2024 | Not recorded | Chair to Secretary of State for Health and Social Care on Future Cancer 23.05.24 |